Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation.
J Cell Biol. 2003 Jul 21;162(2):281-91. doi: 10.1083/jcb.200212141.
J Cell Biol. 2003.
PMID: 12876277
Free PMC article.
Regulation of the protein kinase Raf-1 by oncogenic Ras through phosphatidylinositol 3-kinase, Cdc42/Rac and Pak.
Sun H, King AJ, Diaz HB, Marshall MS.
Sun H, et al. Among authors: diaz hb.
Curr Biol. 2000 Mar 9;10(5):281-4. doi: 10.1016/s0960-9822(00)00359-6.
Curr Biol. 2000.
PMID: 10712905
Free article.
Item in Clipboard
LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms.
King C, Diaz HB, McNeely S, Barnard D, Dempsey J, Blosser W, Beckmann R, Barda D, Marshall MS.
King C, et al. Among authors: diaz hb.
Mol Cancer Ther. 2015 Sep;14(9):2004-13. doi: 10.1158/1535-7163.MCT-14-1037. Epub 2015 Jul 3.
Mol Cancer Ther. 2015.
PMID: 26141948
Item in Clipboard
Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.
King C, Diaz H, Barnard D, Barda D, Clawson D, Blosser W, Cox K, Guo S, Marshall M.
King C, et al.
Invest New Drugs. 2014 Apr;32(2):213-26. doi: 10.1007/s10637-013-0036-7. Epub 2013 Oct 10.
Invest New Drugs. 2014.
PMID: 24114124
Item in Clipboard
LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
Barnard D, Diaz HB, Burke T, Donoho G, Beckmann R, Jones B, Barda D, King C, Marshall M.
Barnard D, et al. Among authors: diaz hb.
Invest New Drugs. 2016 Feb;34(1):49-60. doi: 10.1007/s10637-015-0310-y. Epub 2015 Nov 27.
Invest New Drugs. 2016.
PMID: 26612134
Item in Clipboard
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.
Calvo E, Chen VJ, Marshall M, Ohnmacht U, Hynes SM, Kumm E, Diaz HB, Barnard D, Merzoug FF, Huber L, Kays L, Iversen P, Calles A, Voss B, Lin AB, Dickgreber N, Wehler T, Sebastian M.
Calvo E, et al. Among authors: diaz hb.
Invest New Drugs. 2014 Oct;32(5):955-68. doi: 10.1007/s10637-014-0114-5. Epub 2014 Jun 20.
Invest New Drugs. 2014.
PMID: 24942404
Clinical Trial.
Item in Clipboard
Cite
Cite